NRx Pharmaceuticals, Inc.
NRXP
$2.75
$0.124.56%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.70M | 12.20M | 13.51M | 12.78M | 12.86M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 14.13M | 17.45M | 19.70M | 20.48M | 23.26M |
| Operating Income | -14.13M | -17.45M | -19.70M | -20.48M | -23.26M |
| Income Before Tax | -33.79M | -24.11M | -25.13M | -20.38M | -24.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -33.79 | -24.11 | -25.13 | -20.38 | -24.82 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -33.79M | -24.11M | -25.13M | -20.38M | -24.82M |
| EBIT | -14.13M | -17.45M | -19.70M | -20.48M | -23.26M |
| EBITDA | -14.13M | -17.45M | -19.70M | -20.47M | -23.26M |
| EPS Basic | -2.21 | -1.98 | -2.38 | -2.17 | -2.77 |
| Normalized Basic EPS | -1.10 | -1.14 | -1.41 | -1.42 | -1.68 |
| EPS Diluted | -2.21 | -1.98 | -2.38 | -2.17 | -2.77 |
| Normalized Diluted EPS | -1.10 | -1.14 | -1.41 | -1.42 | -1.68 |
| Average Basic Shares Outstanding | 57.57M | 50.15M | 42.59M | 38.41M | 35.64M |
| Average Diluted Shares Outstanding | 57.57M | 50.15M | 42.59M | 38.41M | 35.64M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |